Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- METTL 16 methyl transferase m6 A premRNA MAT 2A U 6 sn RNA MALAT 1 noncoding Inc Mat 2a METT 10D EC2.1.1.346 EC2.1.1.62
- Product Overview:
Methyltransferase-like protein 16 (METTL16) is an m6A RNA methyltransferase encoded by the METTL16 gene in humans and localized to the cell nucleus.{50141,56098} It is composed of a methyltransferase domain that associates with RNA and two vertebrate conserved regions (VCRs) on the C-terminal end that promote splicing.{49283} METTL16 acts as an epigenetic writer by methylating the pre-mRNA of the S-adenosylmethionine (SAM) synthetase MAT2A in the presence of SAM. It also methylates the adenine at position 43 of spliceosome component U6 snRNA and interacts with cancer-associated MALAT1 long non-coding RNA (lncRNA).{35512,50141} Knockout of Mettl16 in mouse embryos leads to a reduction in Mat2a mRNA expression, transcriptome dysregulation, and lethality at approximately the implantation stage.{49284} The expression of METTL16 is increased in isolated human colon, but not rectal, adenocarcinoma tumor tissue, and decreased METTL16 expression in rectal adenocarcinoma tumor tissue is associated with lower overall survival.{49285} Cayman’s METTL16 Monoclonal Antibody can be used for ELISA, Immunofluorescence, and Western blot applications. The antibody recognizes METTL16 at 64 kDa from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.